Skip to main content

Table 2 Dosage inhibitory effects of both EGCG and DOX on the cells (n = 5)

From: SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition

Drug

Concentration

Growth inhibitory effects (OD)

CDI

U2OS

 DOX

0 μM

0.876 ± 0.042

–

1 μM

0.750 ± 0.027

–

2.5 μM

0.670 ± 0.023

–

 DOX + EGCG

0 μM + 20 μg/ml

0.763 ± 0.046

–

1 μM + 20 μg/ml

0.515 ± 0.008

0.904 ± 0.053

2.5 μM + 20 μg/ml

0.430 ± 0.019

0.855 ± 0.052

SaoS2

 DOX

0 μM

1.224 ± 0.050

–

1 μM

1.014 ± 0.018

–

2.5 μM

0.853 ± 0.012

–

 DOX + EGCG

20 μg/ml

1.190 ± 0.054

–

1 μM + 20 μg/ml

0.957 ± 0.032

0.794 ± 0.035

2.5 μM + 20 μg/ml

0.793 ± 0.024

0.782 ± 0.036

  1. Drug interaction was measured as described in materials and methods with increasing concentrations DOX or both agents for 48 h. CDI<1 indicates a synergistic effect, CDI = 1 indicates an additive effect, CDI>1 indicates an antagonistic effect